These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Author: Chuang JC, Neal JW, Niu XM, Wakelee HA.
    Journal: Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476.
    Abstract:
    Tyrosine kinase inhibitors (TKIs) against targetable mutations such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are highly effective in treating advanced stage lung cancers harboring such mutations. Questions remain, however, about whether these agents can improve cure rates for early stage lung cancers in the adjuvant setting. Here, we examine the current data and ongoing trials addressing this issue.
    [Abstract] [Full Text] [Related] [New Search]